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Abstract  
The prevention of implant-associated infection, one the most feared complications in orthopaedic 
surgery, remains a major clinical challenge and urges development of effective methods to prevent 
bacterial colonization of implanted devices. Alpha-helical antimicrobial peptides (AMPs) may be 
promising candidates in this respect due to their potent and broad-spectrum antimicrobial activity, 
their low tendency to elicit resistance and possible retention of efficacy in the immobilized state. 
The aim of this study was to evaluate the potential of five different helical AMPs, the cathelicidins 
BMAP-27 and BMAP-28, their (1-18) fragments and the rationally designed, artificial P19(9/G7) 
peptide, for the prevention of orthopaedic implant infections. Peptides were effective at micromolar 
concentrations against 22 Staphylococcus and Streptococcus isolates from orthopaedic infections, 
while only BMAP-28 and to a lesser extent BMAP-27 were active against Enterococcus faecalis. 
Peptides in solution showed activities comparable to those of cefazolin and linezolid, on a molar 
basis, and also a variable capacity to neutralize bacterial lipopolysaccharide, while devoid of 
adverse effects on MG-63 osteoblast cells at concentrations corresponding to the MIC. The (1-18) 
BMAP fragments and P19(9/G7) were selected for further examination, based on better selectivity 
indices, and showed effectiveness in the presence of hyaluronic acid and in synovial fluid, while 
human serum affected their activity to variable extents, with BMAP-27(1-18) best retaining activity. 
This peptide was immobilized on streptavidin-resin beads and retained activity against reference S. 
epidermidis and S. aureus strains, with negligible toxicity towards osteoblasts, underlining its 
potential for the development of infection-resistant biomaterials for orthopaedic application.  
 
Keywords: α-helical antimicrobial peptide, prosthetic joint pathogens, Staphylococcus, human 
serum, hyaluronic acid, peptide immobilization. 
 
 
Abbreviations: ALP, alkaline phosphatase; AMP, antimicrobial peptide; BHI, Brain-Heart 
Infusion; CFU, colony-forming unit; CLSI, Clinical and Laboratory Standards Institute; DEG, 
diethylene glycol; DMEM, Dulbecco's Modified Eagle's Medium; DMF, N,N-dimethylformamide; 
DXM, dexamethasone; FBS, foetal bovine serum; HA, hyaluronic acid; HBSS, Hanks' Balanced 
Salt Solution; HPLC, high performance liquid chromatography; HS, human serum; HSA, human 
serum albumin; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; MBC, minimum 
bactericidal concentration; MH, Mueller-Hinton; MIC, minimum inhibitory concentration; MRSA, 
methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus 
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epidermidis; NO, nitric oxide; OM, osteogenic medium; PBS, phosphate buffered saline; RPMI, 
Roswell Park Memorial Institute; SF, synovial fluid; SD, standard deviation; TFA, trifluoroacetic 
acid.  
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Introduction 
Implant-associated infection is a major challenge in orthopaedic surgery. Although it occurs 
in only a small proportion of cases, infection of prosthetic joints is a feared and devastating 
complication of arthroplasty procedures and is associated with substantial morbidity and a huge 
economic burden [1-3]. The incidence of infection can be much higher following trauma surgery, 
such as fracture fixation [4]. More than half of infections are caused by Gram-positive cocci, the 
most common being coagulase-negative Staphylococcus spp. and Staphylococcus aureus, followed 
by Streptococcus and Enterococcus spp. A relevant proportion of these is polymicrobial, often 
involving methicillin-resistant S. aureus (MRSA). Gram-negative bacilli, anaerobes and fungi are 
less frequent causative agents [1, 3]. Treatment of infections associated with orthopaedic devices is 
challenging as bacteria tend to grow in biofilms, which reduces antibiotic efficacy, added to which 
is the growing incidence of antibiotic resistance also in orthopaedic settings [1, 3, 5]. The 
prevention of initial bacterial colonization of the implant surface thus remains a priority. 
In this respect, natural antimicrobial peptides (AMPs) may represent a valuable reservoir of 
lead compounds for the development of novel anti-infective agents. AMPs comprise structurally 
diverse molecules endowed with potent microbicidal properties, acting as relevant components of 
the immune system in a wide range of living organisms [6]. Unlike conventional antibiotics, which 
act on specific bacterial targets, the mode of action of AMPs in most cases relies on their capacity 
to selectively perturb bacterial membranes, owing to their cationic and amphipathic nature [6, 7]. 
This mechanism accounts for their broad spectrum of activity and efficacy also against antibiotic-
resistant strains, as well as for their low propensity to promote bacterial resistance [7]. Additionally, 
in several instances AMPs have exhibited immunomodulatory properties due to their ability to 
interact with host cells and modulate their functions, without damaging them [8, 9]. Several natural 
or artificial AMPs are currently under preclinical or clinical development as novel anti-infectives [6, 
9, 10]. Moreover, an emerging approach focuses on exploiting these molecules for the fabrication of 
infection-resistant biomaterials for medical use [10-12].  
Among the diverse structural classes of AMPs, linear peptides adopting an α-helical 
conformation appear to possess the most robust antimicrobial activities, with lower susceptibility to 
medium conditons [13, 14]. In addition to broad-spectrum activity, they can bind and neutralize 
proinflammatory bacterial components such as lipopolysaccharide (LPS) [9, 15]. Given their 
abundance in nature and their relatively easy chemical production with respect to other structural 
classes, native peptide sequences have been exploited as templates for numerous synthetic helical 
AMPs with optimized structural parameters to enhance antimicrobial potency and selectivity [16, 
17]. As their killing mechanism does not require internalization by target bacteria, α-helical AMPs 
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may retain activity upon immobilization, which may render them suitable for the development of 
antimicrobial surfaces [18-20]. 
In the present study five cationic α-helical AMPs, i.e., two bovine members of the 
cathelicidin AMP family [21], two shorter derivatives [22] and a rationally designed artificial AMP 
[17], have been evaluated for potential applications in the prevention of orthopaedic device-related 
infections. Antimicrobial efficacy of peptide candidates has been assayed against bacterial isolates 
from clinical cases of orthopaedic infection, in comparison with two conventional antibiotics. The 
peptides were also evaluated for LPS-neutralizing capacity and for potential effects on osteoblast 
viability and differentiation. Based on their more favourable selectivity indices the study was then 
narrowed to the three shorter peptide candidates, that were examined for antimicrobial efficacy 
under conditions more closely resembling those encountered in vivo in arthroplasty settings. The 
peptide with the best activity overall was then tethered to resin beads via streptavidin-biotin 
technology to obtain a proof-of-concept demonstration of antimicrobial efficacy upon 
immobilization. 
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Materials and methods 
 
Media and reagents 
Derivatized polyethylene glycol–polystyrene (PEG-PS) resins, coupling reagents for peptide 
synthesis and 9-fluorenylmethoxy carbonyl (Fmoc)-amino acids were purchased from Applied 
Biosystems/Thermo Fisher Scientific (Waltham, MA, USA), Novabiochem (Laufelfingel, 
Switzerland) and ChemImpex (Wood Dale, IL, USA). Peptide synthesis-grade N,N-
dimethylformamide (DMF), dichloromethane, piperidine and HPLC-grade acetonitrile were from 
Biosolve (Valkenswaard, The Netherlands). Trifluoroacetic acid (TFA), trifluoroethanol and N-
methylmorpholine were from Acros Chimica (Beerse, Belgium). The biotinylating reagents D(+)-
Biotin and O-(N-Biotinyl-3-aminopropyl)-O’-(N-glutaryl-3-aminopropyl)-diethyleneglycol (N-
Biotinyl-NH-PEG2-COOH) were obtained from Calbiochem (La Jolla, CA, USA) and 
Novabiochem, respectively. High-performance Streptavidin-Sepharose
TM
 resin was purchased from 
GE Healthcare Life Sciences (Little Chalfont, Buckinghamshire, UK). 
Dehydrated media for microbiological assays were obtained from Difco laboratories (Detroit, MI, 
USA) and Oxoid/Thermo Fisher Scientific. Cefazolin sodium salt, linezolid, lipopolysaccharide 
(LPS) from E. coli O111:B4, dexamethasone (DXM), hyaluronic acid sodium salt (HA) and normal 
human serum (HS) were from Sigma-Aldrich (St. Louis, MO, USA). Media and supplements for 
cell culture were from Sigma-Aldrich with the exception of foetal bovine serum (FBS) (Euroclone, 
Pero, Italy). Unless otherwise specified, FBS and HS were inactivated at 56°C for 30 min prior to 
use. Synovial fluid (SF) samples were obtained with informed consent at Udine University Hospital 
(Udine, Italy); samples were centrifuged, aliquoted and stored at -80°C. 
The Griess and PrestoBlue® reagents were from Molecular Probes/Thermo Fisher Scientific and 
Invitrogen/Thermo Fisher Scientific, respectively. The CytoTox 96® Non-Radioactive Cytotoxicity 
Assay kit was from Promega (Madison, WI, USA). All other reagents, including p-Nitrophenyl 
Phosphate Liquid Substrate System, were from Sigma-Aldrich. Buffers were prepared in double 
glass-distilled water. 
 
Peptide synthesis and characterization 
Peptides (Table 1) were synthesized in the solid phase using the Fmoc-chemistry. Difficult coupling 
steps were handled as described previously [14, 23]. BMAP-27 and BMAP-27(1-18) were 
biotinylated by coupling 5 equivalents of D(+)-Biotin to the N-terminus of resin-bound peptides in 
the presence of equimolar 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoro-borate 
(TBTU) and 1H-hydroxybenzotriazole (HOBt) in DMF containing 0.6 N N-methylmorpholine for 4 
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h at room temperature. BMAP-27(1-18) was alternatively biotinylated with N-Biotinyl-NH-PEG2-
COOH using the same procedure. The biotinylated peptides are referred to as biot-B27, biot-B27(1-
18) and biot-DEG-B27(1-18) in the following sections. After cleavage and deprotection, the 
peptides were HPLC-purified and confirmed by mass spectrometry using a Q-STAR hybrid 
quadrupole time-of-flight mass spectrometer (Applied Biosystems/MDS Sciex, Concord, ON, 
Canada) equipped with an electrospray ion source. Peptide concentrations were determined in 
aqueous solution by measuring the absorbance at 257 nm (Phe residues) for BMAP-27 and BMAP-
27(1-18), and at 280 nm (Tyr and Trp residues) for BMAP-28, BMAP-28(1-18) and P19(9/G7) [14, 
23]. 
 
Peptide immobilization on Streptavidin-Sepharose resin 
250 µL of 1 mM solutions of the biotinylated peptides [i.e., biot-B17, biot-B27(1-18) and biot-
DEG-B27(1-18)] in PBS were mixed with an equal volume of high performance Streptavidin-
Sepharose resin (previously washed free of the storage buffer) resuspended in PBS, and allowed to 
react overnight at 4°C under gentle agitation. One resin sample was coupled in parallel with D(+)-
Biotin for use as a reference control. Samples were then allowed to re-equilibrate at room 
temperature, centrifuged and washed extensively with PBS until the absorbance at 257 nm of the 
resin supernatants reached the baseline level. Resin samples were then resuspended in PBS and 
either tested immediately, or stored at 4°C for up to 1 month before use. 
The amount of immobilized peptide was estimated after peptide elution from a resin aliquot by 15 
min treatment with 0.05% (v/v) TFA and lyophilization. The lyophilized eluates were redissolved in 
water and assayed using the Bradford reagent with reference to standard curves generated by serial 
dilutions of the corresponding soluble peptides. 
 
Bacteria and culture conditions 
The reference strains were Staphylococcus epidermidis ATCC 12228 and ATCC 35984, 
Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922 and Pseudomonas aeruginosa 
ATCC 27853. Clinical bacterial isolates were collected from hip revision and other orthopaedic 
surgery at the Valdoltra Orthopaedic Hospital (Ankaran, Slovenia) and the Udine University 
Hospital (Udine, Italy), and included 8 strains of Staphylococcus epidermidis, 8 strains of 
Staphylococcus aureus, 1 strain each of Staphylococcus capitis, Staphylococcus hominis and 
Staphylococcus caprae, 2 strains of Streptococcus agalactiae, 1 group G Streptococcus and 2 
isolates of Enterococcus faecalis. Bacteria were maintained on Mueller-Hinton (MH) agar plates. 
One isolate of S. epidermidis from the Udine hospital was methicillin-resistant as assessed 
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according to the guidelines and interpretative tables of the Clinical and Laboratory Standards 
Institute (CLSI). Bacteria were cultured in either liquid Brain Hearth Infusion (BHI) 
(Staphylococcus, Streptococcus and Enterococcus strains) or MH broth (E. coli and P. aeruginosa) 
for 18 h, 1:50-diluted in fresh medium and allowed to grow in an orbital shaker at 37°C. Mid-log 
phase bacteria were harvested after 10 min centrifugation at 1000 × g and resuspended in MH broth 
to an optimal density before use in antimicrobial assays. Bacterial density was assessed by turbidity 
at 600 nm, with reference to previously determined standards. For biofilm experiments, the bacterial 
inoculum was prepared essentially according to Pompilio et al. [24], by direct suspension of 
colonies grown overnight on MH plates in liquid medium. 
 
Antimicrobial assays 
The minimum inhibitory concentration (MIC) of the peptides in solution was determined by a broth 
microdilution assay in 96-well microtiter plates, using MH broth with logarithmic-phase 
microorganisms at 2.5 × 10
5
 CFU/mL, as previously reported [14], following CLSI guidelines. The 
clinically used antibiotics cefazolin and linezolid were tested in parallel for comparison. The 
minimum bactericidal concentration (MBC) was determined by plating aliquots from wells showing 
no visible growth on solid medium to allow colony counts. 
 
Assays for inhibition of biofilm formation  
50 µL of a S. epidermidis ATCC 35984 suspension (2 × 10
6
 CFU/mL in MH broth), prepared as 
described above, was dispensed into flat-bottomed 96-well microtiter plates containing 50 µL in 
MH of each test agent, at 2× the final dose. Plates were then incubated for 24 h at 37°C, followed 
by removal of non-adherent bacteria by aspiration and rinsing with PBS. Fresh MH broth was then 
added and adherent cells were quantified using the PrestoBlue cell viability reagent according to the 
manufacturer’s specifications. 
 
Bacterial growth kinetics analysis 
Serial dilutions of peptides, at 2× the final concentration, were prepared in 50 µL PBS alone or in 
PBS supplemented either with 1 or 6 mg/mL hyaluronic acid (HA) (leading to 0.5 and 3 mg/mL 
final HA concentrations, respectively), or with 50% human serum (HS, 25% final concentration), or 
with 40% synovial fluid (SF, 20% final concentration) in U-bottom 96-well plates. 50 µL of 
adjusted suspensions of S. epidermidis ATCC 35984 or S. aureus ATCC 25923 in MH broth were 
added to each well to achieve the final density of 1 × 10
7
 CFU/mL. Plates were then sealed with 
optically-clear plastic films to avoid evaporation, and bacterial growth was monitored at 600 nm for 
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6 h at 37°C, with 10-sec shaking steps at 15-min intervals. Bacteria grown in each medium in the 
absence of peptides served as growth controls. In some experiments peptide dilutions in the selected 
media were pre-incubated for 3 h at 37°C prior to the addition of bacteria. Data are reported either 
as growth curves, or as the calculated percent growth inhibition at 6 h with respect to bacteria 
incubated in corresponding media in the absence of peptides. 
 
Antibacterial activity of immobilized peptides 
10 µL aliquots of peptide-functionalized Streptavidin-Sepharose resins (5% v/v final resin 
concentration), or the corresponding supernatants, were diluted in PBS to a final volume of 100 µL 
in microcentrifuge tubes and supplemented with 100 µL of a 2 × 10
7 
CFU/mL suspension of S. 
epidermidis ATCC 35984 or S. aureus ATCC 25923 in MH broth. Bacterial viability was assessed 
after 1 h incubation at 37°C on a rotating wheel by the PrestoBlue assay and CFU counts. 
 
Cell culture and stimulation 
The murine macrophage-like RAW 264.7 and the human osteoblast-like MG-63 cell lines were 
obtained from ATCC (Manassas, VA, USA) and maintained in RPMI-1640 and DMEM medium, 
respectively, in a humidified incubator at 37°C and 5% CO2 atmosphere. Both media were 
supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 units/mL penicillin and 100 µg/mL 
streptomycin (complete media). 
To analyze the effects on LPS-induced nitric oxide (NO) production, RAW 264.7 cells were seeded 
in 24-well plates at a density of 9 × 10
5
 cells /well, cultured overnight and treated for 24 h with 100 
ng/mL LPS in the absence and presence of peptides at the indicated concentrations, in complete 
RPMI. 
MG-63 cells used for cell viability and cytotoxicity assays were seeded in 96-well plates at a 
density of 7500/well and grown for 24 h in complete DMEM before being incubated with 
increasing peptide concentrations in complete medium, or, alternatively, in DMEM supplemented 
with 10% (v/v) HS, or in HBSS supplemented with 10% HS in the absence and presence of 0.5 
mg/mL HA. Peptide-functionalized resins were tested at 5% (v/v) in complete medium. Incubation 
times were 1 h and 24 h for lactate dehydrogenase (LDH) release and cell viability assays, 
respectively. 
For osteoblast differentiation experiments, MG-63 cells were seeded in 24-well plates at a density 
of 3 × 10
5
 /well in complete medium, grown to 80% confluence and incubated for 7 days in serum-
free DMEM supplemented with 10 mM β-glycerophosphate and 50 µg/mL L-ascorbic acid 
(osteogenic medium, OM) in the absence or presence of 2 µM peptides, of 100 nM dexamethasone 
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(DXM, positive control) or a combination of peptides and DXM. During the incubation period 
medium was replaced twice with fresh OM supplemented with the stimuli. 
 
Nitric oxide (NO) determination 
The amount of NO released by LPS- and peptide-treated RAW 264.7 cells was estimated by 
spectrophotometric quantification of the stable NO metabolite nitrite in the cell culture supernatants 
using the Griess reagent. Data were expressed as percent of nitrite produced in response to LPS in 
the absence of peptides. 
 
Cytotoxicity and cell viability assays 
Membrane damage to MG-63 cells was evaluated as leakage of the cytosolic enzyme lactate 
dehydrogenase (LDH). LDH activity was quantified in both cell-free supernatants and cell lysates 
using the CytoTox 96 Non-Radioactive Cytotoxicity Assay kit. Data were calculated as percentage 
of total cellular LDH activity. Cell viability was assessed using the resazurin-based PrestoBlue 
metabolic dye according to the manufacturer's instructions. 
 
Measurement of alkaline phosphatase (ALP) activity 
MG-63 cells, incubated in OM with peptides and DXM as described above, were harvested by 
trypsinization, resuspended in water and sonicated. Lysate proteins were quantified by the Bradford 
assay. ALP activity was assessed spectrophotometrically from the transformation of p-nitrophenyl 
phosphate to p-nitrophenol at 37°C. Briefly, 10 µg protein aliquots of cell lysates were diluted in 
water in microtiter plates to a final volume of 50 µL, mixed with 150 µL of p-Nitrophenyl 
Phosphate Liquid Substrate System and incubated for 80 min at 37°C. Absorbance was read at 405 
nm and compared to a p-nitrophenol standard curve. Data were calculated as nmoles/mg/min and 
expressed as fold-increase with respect to basal ALP activity, or as percent of ALP activity induced 
by DXM alone. 
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Results 
 
Design and selection of candidate peptides 
The peptides used in this study (Table 1) were selected on the basis of their reported broad 
antimicrobial activity spectra that covered Gram-positive cocci [17, 22, 23, 25]. BMAP-27 and 
BMAP-28 are amphipathic α-helical bovine cathelicidins that were previously shown to exert 
potent bactericidal activity based on rapid membrane permeabilization [22, 25]. The two shorter 
derivatives, BMAP-27(1-18) and BMAP-28(1-18) (hereafter referred to as B27(1-18) and B28(1-
18)), were synthetically more accessible and showed improved selectivity with respect to 
prokaryotic cells [22]. The peptide P19(9/G7) (hereafter P19) was rationally designed based on a 
consensus sequence derived from a panel of over 100 of natural helical AMPs of invertebrate, 
anuran and mammalian origin [17, 23]. This peptide is based on an amidated, 18-residue sequence, 
like the BMAP fragments, with an added C-terminal Tyr residue to improve quantification 
accuracy. 
 
Antimicrobial activity against orthopaedic pathogens 
The MIC and MBC values of the peptides towards representative reference strains of Gram-
positive S. epidermidis and S. aureus and Gram-negative E. coli and P. aeruginosa are reported in 
Table 2. Based on the frequent presence of Gram-positive microorganisms among the causative 
agents of orthopaedic device-related infections [1, 3], the peptides were assayed against a panel of 
Gram-positive clinical isolates from such infections, including Staphylococcus, Streptococcus and 
Enterococcus species (Table 3). All peptides proved effective at low micromolar concentrations 
against most strains, with MBC values very close to the MICs, with the exception of E. faecalis, 
which was susceptible only to BMAP-28 and to a lesser extent to BMAP-27. On a molar basis, their 
potency was comparable to cefazolin and linezolid, two conventional antibiotics used in 
orthopaedic practice [26, 27]. Considering S. aureus and S. epidermidis species, susceptibility of 
clinical isolates and corresponding reference strains to the AMPs was similar. Among the peptides, 
the rationally designed P19 was overall somewhat less effective against S. aureus, while its activity 
against the other Staphylococcus strains was comparable to that of the BMAP peptides. In general, 
peptides were highly active against S. epidermidis, whereas somewhat higher MIC values were 
observed against S. aureus isolates. In addition, all peptides prevented the formation of S. 
epidermidis ATCC 35984 biofilm at their MIC values, as shown in Figure 1a. Cefazolin and 
linezolid, tested in parallel, resulted in complete biofilm inhibition at 16 µM (4-fold MIC) and 6 µM 
(MIC), respectively (Figure 1b and data not shown). 
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Neutralization of bacterial lipopolysaccharide 
Peptides were next evaluated for their ability to neutralize the effects of bacterial 
lipopolysaccharide (LPS), an activity common to several amphipathic helical AMPs [15] that could 
be advantageous in the context of orthopaedic biomaterials [28-30]. This was tested by inhibition of 
LPS-induced nitric oxide (NO) release from RAW 264.7 macrophage-like cells co-stimulated with 
peptides and LPS. BMAP-27 and -28 completely abolished the NO response at concentrations as 
low as 0.5 - 1 µM (Fig. 2), consistent with previous reports on their direct LPS-binding properties 
[31-33]. Among the three shorter peptides, B28(1-18) virtually abolished the LPS-induced response 
at 2 µM, while B27(1-18) and P19 respectively caused 80% and 66% inhibition at 8 µM (Fig. 2). 
These results could not be ascribed to cytotoxic effects on the RAW cells, as cell viability was not 
impaired under the experimental conditions used (resazurin-based metabolic assays, data not 
shown). 
 
Effects on osteoblast viability and differentiation 
To assess their safety for orthopaedic applications, the effects of peptides on osteoblast cells 
were investigated using the human osteosarcoma-derived MG-63 cell line, as a well-established in 
vitro osteoblast model [34, 35]. Potential short- and long-term effects were assessed in terms of 
membrane damage, cell viability and cell differentiation. Figure 3a shows the percentage of lactate 
dehydrogenase (LDH) release by cells incubated with the peptides for 1 h in standard cell culture 
medium, as an indicator of impaired plasma membrane integrity. None of the peptides caused 
detectable LDH release at concentrations in each peptide’s MIC range (cf. Fig. 3a and Table 3). The 
shorter BMAP derivatives were safe up to 10 µM, while the parent peptides caused 38-54% LDH 
release at this concentration. P19 did not cause detectable effects up to at least 20 µM (Fig. 3a). 
Remarkably, the toxicity of full-length and truncated BMAPs was clearly reduced when using 
human rather than standard foetal bovine serum in the cell culture medium (Fig. 3c), indicating that 
the range of safe concentrations under conditions relevant to in vivo settings could actually be 
wider. To mimic the joint environment, peptides were assayed in Hanks’ Balanced Salt Solution 
(HBSS) supplemented with human serum (HS) and hyaluronic acid (HA) at 0.5 mg/mL, a 
concentration reflecting those found in periprosthetic synovial fluid [36]. Under these conditions, 
peptides were safe up to 10 µM with the exception of BMAP-27, which caused approximately 40% 
and 68% LDH release at 10 and 20 µM, respectively (Fig. 3d). The three shorter peptides, and in 
particular P19 and B27(1-18), showed lower overall toxicity. This was also confirmed in terms of 
cell viability after 24 h incubation with 1.25 - 10 µM peptides in standard culture medium, which 
indicated the impairment of cell viability only on treatment with the full-length BMAPs at the 
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highest tested concentration (Fig. 3b). Long-term effects on osteoblast cells were also addressed by 
measuring alkaline phosphatase (ALP) activity as a differentiation marker for these cells [37]. 
Peptides were evaluated in comparison with dexamethasone (DXM) as a reference osteogenic 
stimulus [37]. MG-63 cells incubated for 7 days with 2 µM peptides in osteogenic medium showed 
comparable ALP activity as control cells except after treatment with BMAP-27, which caused an 
approximately 50% reduction in activity (Fig. 3e). A 2.7-fold increase in ALP activity was detected 
in DXM-treated cells (Fig. 3e). The three shorter peptides were further investigated in combination 
with the latter stimulus, showing no significant effects on the DXM-induced response (Fig. 3f), 
suggesting they would not be detrimental to the osseointegration processes.  
 
Antimicrobial activity in the presence of hyaluronic acid, synovial fluid and blood serum 
Given their compatibility with osteoblast cells, the (1-18) BMAP derivatives and P19 were 
subjected to further investigation. Their antimicrobial efficacy against S. epidermidis ATCC 35984 
and S. aureus ATCC 25923 was assayed in the presence of HA (as it could interact electrostatically 
with the cationic peptides due to its negative charge), used at 0.5 and 3 mg/mL to mimic 
periprosthetic and normal synovial fluid concentrations, respectively [36, 38]. Figure 4 shows 
growth kinetics analyses in the presence of increasing peptide concentrations, expressed as percent 
growth inhibition after 6 h incubation in each media. HA per se did not significantly affect bacterial 
growth (data not shown). Remarkably, all of the peptides retained full activity against both 
Staphylococcus species under these conditions. Furthermore, full peptide efficacy was retained even 
after 3 h pre-incubation of peptides with HA (6 mg/mL) before the addition of the bacterial 
suspension (data not shown), suggesting that peptides should retain efficacy in the joint 
environment, where HA is a relevant component. This was further supported by growth kinetics 
analysis of S. aureus ATCC 25923 incubated with the peptides in the presence of a clinical sample 
of synovial fluid (SF, 20%) (Fig. 5). A limited number of SF samples were available, showing a 
rather variable intrinsic inhibition of bacterial growth (data not shown); the one that was chosen for 
the reported experiment allowed an appreciable S. aureus growth within the 6 h experimental time 
frame. Peptides, tested at 2 µM in its presence instead completely prevented bacterial growth (Fig. 
5). 
The applicative potential of the peptides was next assessed by antimicrobial assays 
performed in the presence of human serum (HS), based on reported evidence of inhibitory effects of 
serum components on AMP activity [14, 39-41]. Figure 6 shows the percentage of growth 
inhibition of S. epidermidis and S. aureus incubated for 6 h with increasing peptide concentrations 
in the absence and presence of commercial pooled human serum at 25%. HS per se did not impair 
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growth of either strain (data not shown), while affecting the peptides’ inhibitory activity to variable 
extents. Complete inhibition of S. epidermidis growth in the presence of HS was achieved at the 
same B27(1-18) concentrations as those effective in its absence, and only slightly higher B28(1-18) 
and P19 concentrations (Fig. 6a, b). In the case of S. aureus, B27(1-18) and P19 showed a two-fold 
increase and B28(1-18) a four-fold increase in the concentrations necessary to obtain complete 
bacterial inhibition (Fig. 6d, e). Notably, when peptides were pre-incubated with 50% HS for 3 h 
prior to addition of the bacterial suspension, all of the peptides were similarly affected, with the 
concentration required for complete inhibition of S. aureus growth increasing to 64 µM (Fig. 6f). 
With respect to S. epidermidis growth inhibition under these conditions, B27(1-18) clearly retained 
the best activity [complete inhibition at 2-4 µM vs >8 µM for B28(1-18) and P19] (Fig. 6c). When 
B27(1-18) efficacy against S. epidermidis was tested in the presence of heat-inactivated HS (as in 
the experiments described thus far) or in the presence of HS not subjected to heat inactivation, 
results were overlapping (data not shown). 
 
Antimicrobial efficacy in the immobilized state 
Considering the overall results obtained thus far, the functional analysis of peptide 
candidates narrowed the choice to B27(1-18) for further evaluation of efficacy upon 
immobilization. Its parental BMAP-27 was previously reported to retain activity when covalently 
linked to a solid surface [19], so it was tested in parallel for comparison. Peptides were N-terminally 
biotinylated and conjugated to a commercial agarose resin functionalized with streptavidin. B27(1-
18) was also derivatized with a biotinylated diethylene glycol (DEG) spacer to favour peptide 
mobility. In solution, the biotinylated derivatives showed comparable MIC values to the 
corresponding non-biotinylated peptides against reference S. epidermidis and S. aureus strains (data 
not shown), indicating that this modification did not alter activity. Peptide-functionalized resin 
samples were incubated with S. epidermidis ATCC 35984 and S. aureus ATCC 25923 suspensions 
for 1 h under agitation. Antibacterial effects were evaluated by the resazurin-based metabolic assay 
and colony counts. As reported in Figure 7a and c, total bacterial inactivation was achieved upon 
exposure to BMAP-27 and B27(1-18)-derivatized resins, while with the DEG-B27(1-18)-
functionalized sample 65% and 33% inhibition of S. epidermidis and S. aureus was respectively 
observed. Consistent with this, CFU counts revealed complete killing in the case of immobilized 
BMAP-27 and B27(1-18), and a partial effect with DEG-B27(1-18) (Fig. 7b, d). It is important to 
note that the control resin, derivatized with biotin only, and the supernatants from peptide-
derivatized resin samples did not affect bacterial viability (Fig. 7a, c). To verify the stability of the 
functionalized resins, their activity against S. epidermidis ATCC 35984 was also measured after 1 
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month storage at 4°C and, as shown in Figure 7e and f, it was fully retained, indicating that the 
peptide-resin coupling is quite stable. This was also supported by the lack of activity of supernatants 
from 1 month-old resin samples (Fig. 7e). Finally, LDH release assays on MG-63 cells incubated 
for 1 h with 5% resin suspensions did not reveal any impairment of cell membrane integrity (Table 
4) supporting compatibility of functionalized resins with osteoblast cells.  
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Discussion 
Surface modifications to render implants refractory to bacterial colonization are among the 
main strategies currently pursued to prevent orthopaedic implant-associated infection  [42, 43]. The 
antimicrobial peptides of innate immunity are receiving increasing attention as novel anti-infective 
agents also in the field of medical devices [8-11]. The aim of the present study was to identify a 
peptide candidate active against relevant orthopaedic implant pathogens under conditions 
resembling in vivo settings, and suitable to be immobilized onto solid supports in view of future 
development of peptide-based infection-resistant biomaterials for orthopaedic applications. 
Five α-helical peptide candidates were compared for their in vitro efficacy against clinically 
relevant Gram-positive bacterial strains isolated from orthopaedic infections. In keeping with 
previous reports, the BMAP peptides displayed similar low micromolar MIC values against most of 
the tested strains under standard conditions [14, 25, 44-46]. The comparable, or only slightly 
decreased potency of the (1-18) BMAP fragments confirms that antimicrobial activity is mainly 
mediated by the N-terminal segment predicted to adopt the amphipathic helical conformation [22, 
25, 33]. In this regard, peptide modifications on parental or truncated BMAPs not subverting the 
overall helical fold were shown to be irrelevant to peptide activity [33, 39, 47, 48], supporting a 
relatively non-specific mode of peptide interaction with bacterial membranes that accounts for 
broad-spectrum permeabilizing effects. 
While showing comparable efficacy to the BMAPs on other tested bacterial species, P19 
displayed a clearly decreased activity against S. aureus strains. This suggests a partially different 
mode of action. Indeed, peptides of the P19 series have been proposed to act on Staphylococcus 
strains by a mechanism dependent on interference with functional processes at membrane level 
rather than on direct permeabilization [49]. 
With the exception of BMAP-28, the peptides under investigation showed lower efficacy 
against the clinical isolates of E. faecalis with P19 being the least effective. Concerning the BMAPs 
and derivatives, despite the limited number of strains tested, the observed MICs and the differences 
in potency are on the whole in line with a previous study assaying their activity against ten E. 
faecalis isolates, including vancomycin-resistant strains [25].  
In general, the peptides under study showed a comparable efficacy to conventional 
antibiotics on a molar basis, and moreover proved effective against a methicillin-resistant clinical 
isolate of S. epidermidis (MRSE). This adds to previous reports on the efficacy of BMAPs and their 
derivatives, as well as of P19, on antibiotic-resistant Gram-positives, including MRSA [23, 25, 44, 
50]. Moreover, peptides prevented S. epidermidis biofilm formation at microbicidal concentrations, 
with an all-or-nothing effect overall, likely due to rapid killing of bacteria before their 
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deposition/attachment to the surface of microplate wells. At variance with the AMPs, both cefazolin 
and linezolid displayed a gradual inhibition of biofilm formation, consistent with a mode of action 
not directly targeting the bacterial membrane [51, 52]. Furthermore, while linezolid was effective at 
preventing biofilm formation also at sub-MIC concentrations, cefazolin showed complete inhibition 
only at 4-fold its MIC. Comparing the efficacy of the peptides to cefazolin, the antibiotic of choice 
in perioperative orthopaedic prophylaxis [26], the selected AMPs appear to be suitable candidates 
for the prevention of bacterial colonization of implanted devices. 
A distinctive feature of cationic AMPs is their capacity to neutralize proinflammatory 
bacterial components such as lipopolysaccharide (LPS, endotoxin) [15]. This property may be 
advantageous for applications in the field of orthopaedic biomaterials since endotoxin 
contamination may be responsible for adverse tissue reactions and can negatively affect the 
osseointegration process [28-30, 53]. Indeed, the murine cathelicidin CRAMP, another α-helical 
cathelicidin that is paralogous to BMAPs, has been shown to inhibit LPS- and flagellin-induced 
osteoclastogenesis by direct neutralization of these bacterial components, and accordingly has been 
proposed to act as a protector of bone resorption induced by bacterial infection in mice [54]. In the 
present study, in comparison to the complete LPS-neutralizing activity of the full length BMAPs, 
the three shorter peptides displayed a lower but appreciable effect. With respect to (1-18) BMAP 
peptides, this residual but still appreciable LPS-neutralizing effect, as already reported by Lee et al. 
[33], is in line with that also reported for the rabbit paralog CAP18, and sheep BMAP ortholog 
SMAP-29 [55]. These latter peptides have been proposed to bear LPS-binding sites, located both at 
the N- and C-terminal ends, that function cooperatively [55]. The lack of the equivalent to one of 
these sites in the (1-18) BMAP fragments could explain their somewhat lower LPS-binding 
capacity compared to the parental molecules. Nevertheless, the residual activity might still be 
relevant in an in-vivo setting, where LPS levels are expected to be significantly lower than those 
normally used in in-vitro assays [56]. 
One of the major drawbacks in the clinical development of AMPs are cytotoxic effects on 
host cells [8, 9], that offsets several beneficial activities on host cell functions, in addition to their 
direct microbicidal properties [8, 9]. In this respect the human cathelicidin LL-37, while exerting 
some toxic effects on osteoblasts [57], has been shown to promote bone regeneration in vivo by 
distinct mechanisms involving stimulation of other cell types [58-60]. In addition, LL-37 has been 
shown to inhibit osteoclastogenesis in vitro [61]. Moreover, the toxic effects of this peptide may be 
counteracted in vivo by endogenous factors [62, 63]. Another class of human AMPs, the beta-
defensins, are reported to display stimulatory effects on osteoblast proliferation and differentiation 
[64]. In the present study, all candidate peptides proved safe to osteoblast cells in their MIC value 
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range, with BMAP fragments and P19 clearly displaying a wider selectivity index. This was 
observed both in standard media and in the presence of human serum and hyaluronic acid as 
relevant factors in view of an orthopaedic application. Our data confirm the improved selectivity of 
BMAP truncated analogs against prokaryotic vs mammalian cells with respect to the parent peptides 
[22, 33]. Moreover, these fragments as well as P19 did not affect osteoblast differentiation per se, 
nor impaired the effect of a recognized osteogenic stimulus [37], which bolsters their suitability for 
applications on orthopaedic devices.  
Although in contrast with several reports on AMP activity being inhibited by anionic 
polysaccharides [65-68], in the present study the activity of B27(1-18), B28(1-18) and P19 against 
S. epidermidis and S. aureus was fully retained in the presence of HA at concentrations 
representative of those found in periprosthetic and normal synovial fluid [36, 38]. The potential for 
peptide efficacy in the skeletal joint environment was further supported by potent activity in the 
presence of a clinical synovial fluid sample, selected among a limited number of available samples 
due to its compatibility with S. aureus growth. Notably, expression of several AMPs was reported 
in both healthy and inflamed synovial membranes and joint fluid [69-71], and this may reasonably 
contribute to the inhibitory effects of joint fluid on microbial growth [72]. In an applicative 
perspective, the presence of endogenous AMPs could be advantageous since they may synergize 
with exogenously introduced AMPs. 
Influence of blood components, e.g., serum albumin and lipoproteins [41, 73, 74], on AMP 
activity represents a crucial issue to be addressed in view of potential therapeutic applications. In 
fact, both BMAP-27 and BMAP-28 have been shown in previous studies to retain antimicrobial 
properties in the presence of heat-inactivated bovine serum, although at higher peptide 
concentrations [14, 39]. In our growth kinetics assays, the AMPs were effective against both 
Staphylococcus species in serum coincubation experiments, at concentrations comparable or only 
slightly higher than those in serum-free medium (see Fig. 6b, e). Peptides showed a more evident 
decrease in potency upon pre-incubation with serum (Fig. 6c, f), but it was interesting to note that 
while a decrease in activity against S. aureus was observed for all the tested AMPs, B27(1-18) was 
the least affected in the case of S. epidermidis. The inhibitory effect of serum on peptide activity 
likely depends on peptide sequestration by serum components, as supported by overlapping activity 
of B27(1-18) against S. epidermidis in the presence of active and heat-inactivated HS, suggesting a 
minimal contribution of enzymatic degradation. In this respect, the different behaviour of B27(1-18) 
towards two Staphylococcus species was rather unexpected, since peptide binding to serum proteins 
would be expected to comparably affect peptide activity regardless of the target microorganism. It 
is widely accepted that membrane-active AMPs exert their microbicidal action through both 
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electrostatic and hydrophobic interactions with bacterial membrane surfaces [6, 7], while binding to 
serum seems preponderantly of a hydrophobic nature [74-76]. As B27(1-18) is the least 
hydrophobic and most cationic of the three shorter AMPs (see Table 1), hydrophobic interactions 
with serum factors may be relatively weaker and electrostatic attractions with the bacterial surface 
play a more dominant role. One could thus reasonably speculate that in the presence of a 
sufficiently anionic bacterial surface, peptide-bacteria interaction would be favoured even in the 
presence of serum.  
According to published reports S. epidermidis has a more anionic surface than S. aureus [77, 
78], which might explain the generally higher activity observed for the three short AMPs against S. 
epidermidis strains as compared to S. aureus (Table 2 and 3). Moreover, for the same reason, S. 
epidermidis could be less prone to shielding by serum, and this is particularly evident for the less 
hydrophobic and more cationic B27(1-18). The competition of serum and bacterial surface for this 
AMP is evidently finely balanced, as the less anionic S. aureus has a more serum-sensitive 
susceptibility to this peptide. A similar hypothesis has been proposed by Huang et al. [73], to 
explain the different susceptibilities of selected bacterial species to a cationic α-helical AMP in the 
presence of human serum albumin (HSA). Notably, in this latter study S. epidermidis was the only 
microorganism whose susceptibility to the peptide was not affected by HSA [73], again indicating 
competitive binding to AMPs of this structural class. 
Due to its better performance under in vivo-mimicking conditions, B27(1-18) was the best 
candidate for further studies with immobilized peptide. Like the parent BMAP-27, reported to 
maintain activity on surface tethering [19], B27(1-18) was bactericidal to both S. epidermidis and S. 
aureus when bound to resin beads. The streptavidin/biotin-based anchoring method, that approaches 
the strength of a covalent bond [79], was selected as being a facile and straightforward procedure, 
suitable for obtaining a proof-of-concept demonstration of peptide efficacy on immobilization [80]. 
In our study, peptides were tethered via the N-terminus as this facilitated the biotinylation 
procedure, also given the reported efficacy of several N-terminally immobilized α-helical AMPs 
[11, 18, 20]. In our hands, immobilization of biotinylated peptides on streptavidin-functionalized 
resin beads led to a highly stable conjugate, as bactericidal activity from free peptide was not 
detected in the resin supernatants, even after a month of storage.  
Comparison between full length surface-linked BMAP-27, surface-linked B27(1-18) and 
also a derivative of the latter with a diethylene glycole spacer [DEG-B27(1-18)] indicated similar 
activity of BMAP-27 and B27(1-18) on both tested strains, whereas DEG-B27(1-18) showed a 
somewhat lower efficacy. This however may be due to a lower peptide-loading on the resin, as 
assessed by peptide quantification upon elution from resin samples. For the DEG-modified peptide, 
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resin loading was assessed to be only 25% that of unmodified B27(1-18) (data not shown). In fact, a 
five-fold increase in DEG-B27(1-18) resin (from 5 to 25%) led to complete inhibition of S. 
epidermidis and an almost 80% reduction of S. aureus viability (data not shown). The reason for 
including a flexible spacer is that it could be relevant to the efficacy of surface-immobilized AMPs 
[11, 12], but in our system activity appeared to be retained also in its absence, in keeping with the 
findings of Rapsch et al. on directly-immobilized α-helical AMPs, including BMAP-27 [19]. In that 
study, immobilized BMAP-27 was significantly less cytotoxic than the soluble counterpart, and was 
proposed to act via bacterial membrane depolarization [19]. Notably, in our study also, none of the 
anchored peptides induced appreciable membrane damage to osteoblast cells. In view of a potential 
application of these peptides in the prevention of orthopaedic device-related infections, surface-
immobilized full-length BMAP-27 and the synthetically more accessible B27(1-18) fragment 
appear to have equivalent antimicrobial efficacy and host-cell compatibility, so that issues related to 
chemical synthesis procedures and production costs would obviously play in favour of the shorter 
analog. 
 
 
Conclusions 
Collectively, the results of this study highlight the potential of the α-helical peptide B27(1-
18) for the prevention of orthopaedic implant-related infections. It effectively killed bacterial 
species responsible for orthopaedic infections and prevented staphylococcal biofilm formation. 
Moreover it attenuated an LPS-induced inflammatory response and was devoid of adverse effects 
on osteoblast cells. Its antimicrobial efficacy was comparable to that of cefazolin, widely used in 
orthopaedic perioperative prophylaxis, and was retained in the presence of relevant biological fluids 
and components. The proof-of-concept demonstration of its efficacy upon immobilization, obtained 
with B27(1-18)-functionalized resin beads, encourages further efforts aimed at tethering this peptide 
onto supports relevant for orthopaedic medical devices, such as titanium or ceramic, in view of the 
development of peptide-based infection-resistant biomaterials for prostheses. 
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Table 1. Peptide sequences and molecular characteristics. 
 
a 
The C-terminus of all peptides is amidated 
b 
q, net charge 
c
 %H, percent hydrophobic residues (sum of A, F, I, L, Y and W residues divided by number of 
residues) 
Peptide Sequencea MW Length qb %Hc 
BMAP-27              GRFKRFRKKFKKLFKKLSPVIPLLHL 3225 26 +12 42 
BMAP-28               GGLRSLGRKILRAWKKYGPIIVPIIRI 3074 27 +8 48 
BMAP-27(1-18)      GRFKRFRKKFKKLFKKLS   2342 18 +11 33 
BMAP-28(1-18)     GGLRSLGRKILRAWKKYG     2058 18 +7 39 
P19(9/G7) GLLKKIGKKAKKALKKLGY  2085 19 +9 42 
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Table 2. Antimicrobial activities against reference strains. 
Organism 
BMAP-27 BMAP-28 B27(1-18) B28(1-18) P19 
MIC (MBC) (µM)a,b 
    S. epidermidis ATCC 12228 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 
    S. epidermidis ATCC 35984 2 (2) 2 (2) 2 (2) 2 (2) 4 (4) 
    S. aureus ATCC 25923 2 (4) 2 (2) 4 (8) 2 (4) 16 (32) 
    E. coli ATCC 25922 1 (1) 2 (2) 2 (2) 1 (1) 2 (2) 
    P. aeruginosa ATCC 27853 2 (4) 4 (16) 2 (4) 2 (4) 2 (2) 
 
a
 Determined in MH broth 
b
 Data are means of at least three independent experiments 
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Table 3. Antimicrobial activities against bacterial isolates obtained from clinical cases of 
orthopaedic infections. 
 
a
 Determined in MH broth 
b
 Data are means of at least three independent experiments 
c
 Methicillin-resistant strain 
d 
MIC50 and MIC90: concentrations that inhibited 50% and 90%, respectively, of the strains 
n.d., not determinable 
Organism 
(no. of isolates) 
BMAP-27 BMAP-28 B27(1-18) B28(1-18) P19 cefazolin linezolid 
MIC range (µM)a,b 
S. epidermidis (8) 0.5-2 (1c) 1-2 (2 c) 0.5-4 (1c) 1-2 (1c) 0.5-32 (1c) 0.5-16 (>16c) <0.4->95 (3c) 
S. aureus (8) 2-4 1-4 2-16 2-8 16->64 0.5-2 6 
other Staphylococcus spp. (3) 0.5-1 1-2 0.5-1 0.5-1 0.5-1 0.5-4 3 
E. faecalis (2) 8-32 4 >64 64 >128 >16 6 
Streptococcus spp. (3) 1-2 0.5-4 1-2 1-2 0.5-2 0.25 1.5-3 
 MBC range (µM)a,b 
S. epidermidis (8) 1-2 (1c) 1-2 (2 c) 0.5-4 (1c) 0.5-4 (1c) 0.5-64 (0.5c) 0.5-16 (>16c) n.d. 
S. aureus (8) 2-4 1-4 2-16 2-8 16->64 1-4 n.d. 
other Staphylococcus spp. (3) 0.5-1 1-2 0.5-1 0.5-1 0.5-1 1->16 n.d. 
E. faecalis (2) 8->32 4 >64 >64 >128 >16 n.d. 
Streptococcus spp. (3) 1-2 2-4 1-2 1-2 0.5-2 1 n.d. 
 MIC50 (MIC90) (µM)
a,b,d 
S. epidermidis (8) 1 (1) 2 (2) 1 (1) 1 (1) 1 (2) 2 (8) 3 (6) 
S. aureus (8) 2 (2) 2 (2) 4 (8) 4 (4) 16 (32) 1 (2) 6 (6) 
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Table 4. Effects of immobilized peptides on cell membrane integrity in osteoblast cells. 
treatmenta % LDH releaseb 
control 3.6 ± 0.8 
resin-biotin 1.7 ± 2.1 
resin-B27  4.9 ± 1.9 
resin-B27(1-18)     3.0 ± 0.3 
resin-DEG-B27(1-18) 2.7 ± 0.3 
 
a 1 h exposure of MG-63 cells to 5% resins in complete medium 
b
 Data were calculated as percentage of total cellular LDH activity, and are the means ± SD of three separate 
experiments 
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Figure captions 
 
Figure 1. Inhibition of S. epidermidis biofilm formation. S. epidermidis ATCC 35984 (1 × 10
6 
CFU/mL in MH broth) was seeded into flat-bottom 96-well polystyrene microtiter plates in the 
absence and presence of the indicated concentrations of peptides (a) or antibiotics (b). Adherent 
bacterial cells were quantified after 24 h incubation by the Prestoblue metabolic assay. Results are 
expressed as percent viability compared to untreated bacteria, and are the means ± SD of three 
independent experiments performed at least in triplicate. 
 
Figure 2. Lipopolysaccharide (LPS) neutralization. RAW 264.7 cells were stimulated with 100 
ng/mL E. coli O111:B4 LPS in complete RPMI, in the absence and presence of peptides at the 
indicated concentrations. Nitrite values were determined in the culture supernatants after 24 h 
incubation using the Griess reagent. Data were calculated as percent of nitrite produced in response 
to LPS in the absence of peptides, and are the means ± SD of three independent experiments. 
 
Figure 3. Effects on osteoblast viability and differentiation. a, c, d) MG-63 osteoblast cells were 
incubated in the absence and presence of the indicated peptide concentrations under the following 
medium conditions: a) DMEM supplemented with 10% FBS (complete medium); c) DMEM 
supplemented with 10% human serum (HS); d) HBSS supplemented with 10% HS and 0.5 mg/mL 
hyaluronic acid (HA). LDH activity was measured in the culture supernatants after 1 h incubation 
and expressed as percentage of total cellular LDH activity. b) Cells were incubated with peptides 
for 24 h in complete medium. Cell viability was evaluated by the Prestoblue metabolic assay and is 
reported as percentage of untreated cells. e, f) Cells were incubated in osteogenic medium (OM) in 
the absence and presence of 2 µM peptides or 100 nM dexamethasone (DXM) (e), or a combination 
of peptides and DXM (f). Alkaline phosphatase (ALP) activity was measured in cell lysates after 7 
days of incubation, and expressed as fold-increase with respect to basal ALP activity (e) or as 
percent of ALP activity induced by DXM alone (f). Data are the means ± SD of three independent 
experiments. 
 
Figure 4. Peptide effects on bacterial growth in the presence of hyaluronic acid (HA). S. 
epidermidis ATCC 35984 (a-c) and S. aureus ATCC 25923 (d-f) (1 × 10
7
 CFU/mL in 50% MH 
broth) were incubated with the indicated concentrations of B27(1-18) (a, d), B28(1-18) (b, e) or P19 
(c, f) in the absence (circles, solid lines) and presence of 0.5 mg/mL (squares, dashed lines) and 3 
mg/mL (triangles, dotted lines) HA. Bacterial growth was monitored for 6 h by optical density (OD) 
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at 600 nm. Data were calculated as percentage of growth inhibition at the 6 h time point with 
respect to bacteria incubated in corresponding media in the absence of peptides. The means ± SD of 
three independent experiments are reported. 
 
Figure 5. Effects on S. aureus growth in the presence of synovial fluid (SF).  S. aureus ATCC 
25923 was incubated at 1 × 10
7
 CFU/mL in 50% MH broth in the absence (closed symbols) and 
presence (open symbols) of 20% synovial fluid and of 2 µM of the indicated peptides. OD readings 
at 600 nm (OD600) at 30 min intervals are reported. 
 
Figure 6. Effects on bacterial growth in the presence of human serum (HS). S. epidermidis 
ATCC 35984 (a-c) and S. aureus ATCC 25923 (d-f) (1 × 10
7
 CFU/mL) were grown in 50% MH 
broth in the absence (a, d) and presence (b, c, e, f) of 25% human serum (HS) and of peptides at the 
indicated concentrations. Bacteria were added immediately after the preparation of peptide dilutions 
in PBS (a, d) or HS-containing PBS (b, e) or, alternatively, were dispensed to the wells after 3 h 
pre-incubation of the peptides at 37°C in the presence of HS (c, f). Bacterial growth was monitored 
for 6 h by OD600 determinations at 30 min intervals. Data were calculated as percentage of growth 
inhibition at 6 h with respect to corresponding controls incubated in the absence of peptides, and are 
the means ± SD of three independent experiments. 
 
Figure 7. Antimicrobial efficacy of biotinylated peptides immobilized on Streptavidin-
Sepharose resin. Streptavidin-Sepharose resin beads functionalized with biotinylated derivatives of 
BMAP-27 and B27(1-18) as described in the method section were assayed for antimicrobial 
efficacy either immediately after completion of the coupling procedure (a-d) or upon 1 month 
storage at 4°C (e, f). S. epidermidis ATCC 35984 (a, b, e, f) and S. aureus ATCC 25923 (c, d) (1 × 
10
7
 CFU/mL in 50% MH broth) were incubated for 1 h with 5% of the indicated resins (closed bars) 
or their respective supernatants (open bars) under gentle agitation. a, c, e) Bacterial viability was 
determined by the Prestoblue metabolic assay and expressed as percent relative to bacteria 
incubated with the control resin functionalized with biotin only, or the corresponding supernatant. b, 
d, f) Bacterial killing in resin-treated samples was determined based on colony counts, and 
expressed relative to the control resin. The means ± SD of three independent experiments are 
reported. 
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Figure 1. Inhibition of S. epidermidis biofilm formation.  
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Figure 2. Lipopolysaccharide (LPS) neutralization.  
 
52x40mm (600 x 600 DPI)  
 
 
Page 33 of 38
http://mc.manuscriptcentral.com/jpsc
Journal of Peptide Science
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
Figure 3. Effects on osteoblast viability and differentiation.  
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Figure 4. Peptide effects on bacterial growth in the presence of hyaluronic acid (HA).  
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Figure 5. Effects on S. aureus growth in the presence of synovial fluid (SF).    
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Figure 6. Effects on bacterial growth in the presence of human serum (HS).  
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Figure 7. Antimicrobial efficacy of biotinylated peptides immobilized on Streptavidin-Sepharose resin.  
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